Cabozantinib, an inhibitor of tyrosine kinase receptors such as c-MET, VEGFR2, AXL, and c-KIT, promotes the growth and progression of HCC and resistance to antiangiogenic therapy [426]. The gene discussed is KIT; the disease is hepatocellular carcinoma.